Merck & Co Inc (LTS:0QAH)
$ 131.3 0 (0%) Market Cap: 249.37 Bil Enterprise Value: 272.91 Bil PE Ratio: 20.67 PB Ratio: 5.61 GF Score: 81/100

Merck & Co Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 13, 2022 / 10:20PM GMT
Release Date Price: $90.23
Chris Shibutani;Robert M. Davis
Goldman Sachs Group, Inc., Research Division - Research Analyst;Merck & Co.,

Okay. I think we're right on time. Welcome, everybody, to the Goldman Sachs Healthcare Conference. It's fantastic to see everybody in person here. We are so pleased to kick off our event today with participation of Merck's CEO, Rob Davis; President of Merck Research Labs, Dean Li. Gentlemen, thank you both for making me (inaudible) here and coming. I know that many of the investors you've been meeting with are also deeply appreciative especially for the time of a CEO to be present here for this event.

Rob, you've been at Merck for a while in the C-suite. The past year, however, has been your opportunity to have the purview of the CEO role, overall, it's a very different place. A lot has happened. Talk to us maybe some opening comments about how you feel Merck's outlook and what you feel are some of your priorities now as we sit here, so that next year when we sit here, once again, I can see how you're progressing on them, but as a CEO now for a year...

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot